Cayman Chemical FSP1 and GPX4 Inhibitor Screening Assay Kits

Cayman Chemical’s ferroptosis suppressor protein 1 (FSP1) and glutathione peroxidase 4 (GPX4) inhibitor screening kits provide a robust and easy-to-use platform for identifying novel inhibitors of human FSP1 and GPX4, which are negative regulators of the ferroptosis pathway.

The FSP1 Fluorescent Inhibitor Screening Assay Kit measures the reduction of resazurin by FSP1 into resorufin, which can be easily quantified using a fluorescence plate reader (Ex/Em = 540/590 nm). The GPX4 Inhibitor Screening Assay Kit measures GPX4 indirectly by a coupled reaction with glutathione reductase. Both kits include the respective FSP1 or GPX4 recombinant human enzyme as well as a known inhibitor as a positive control.

Ferroptosis is a type of non-apoptotic programmed cell death triggered by the iron-dependent accumulation of oxidised lipid membrane polyunsaturated fatty acids. It is triggered by small molecules or conditions that inhibit GPX4 or glutathione biosynthesis. Ferroptosis can be negatively regulated by iron chelators and enzymes that mediate intracellular antioxidant responses, such as FSP1. Certain types of cancer cells are susceptible to ferroptosis when exposed to FSP1 or GPX4 inhibitors, making a screen for compounds that induce ferroptosis relevant to the discovery of anticancer therapies.